NovoCure Ltd $ 145.62 -7.47 (-4.88%)
Volume:
1,342,399
Avg Vol (1m):
696,458
Market Cap $:
14.91 Bil
Enterprise Value $:
14.51 Bil
PE Ratio:
766.41
PB Ratio:
33.96
Current and historical daily P/E ratio for NVCR (NovoCure Ltd) from 2015 to Mar 03 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. NovoCure stock (NVCR) PE ratio as of Mar 03 2021 is 766.41.
More Details
NovoCure PE Ratio (TTM) Chart
EMBED
NovoCure PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1243
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| NovoCure PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2021-03-04 | 766.4 | 2020-12-29 | 889.3 |
| 2021-03-03 | 766.4 | 2020-12-28 | 893.6 |
| 2021-03-02 | 805.7 | 2020-12-24 | 905.1 |
| 2021-03-01 | 802.3 | 2020-12-23 | 898.5 |
| 2021-02-26 | 784.7 | 2020-12-22 | 900.0 |
| 2021-02-25 | 783.7 | 2020-12-21 | 891.9 |
| 2021-02-24 | 911.2 | 2020-12-18 | 843.1 |
| 2021-02-23 | 910.3 | 2020-12-17 | 856.9 |
| 2021-02-22 | 952.8 | 2020-12-16 | 827.0 |
| 2021-02-19 | NaN | 2020-12-15 | 826.8 |
| 2021-02-18 | 924.8 | 2020-12-14 | 889.4 |
| 2021-02-17 | 952.1 | 2020-12-11 | 903.7 |
| 2021-02-16 | 975.3 | 2020-12-10 | 885.2 |
| 2021-02-15 | 998.2 | 2020-12-09 | 847.5 |
| 2021-02-12 | 998.2 | 2020-12-08 | 828.8 |
| 2021-02-11 | 963.6 | 2020-12-07 | 801.7 |
| 2021-02-10 | 962.2 | 2020-12-04 | 776.3 |
| 2021-02-09 | 984.4 | 2020-12-03 | 710.8 |
| 2021-02-08 | 968.2 | 2020-12-02 | 685.4 |
| 2021-02-05 | 925.5 | 2020-12-01 | 668.3 |
| 2021-02-04 | 921.2 | 2020-11-30 | 661.3 |
| 2021-02-03 | 916.0 | 2020-11-27 | 667.6 |
| 2021-02-02 | 915.4 | 2020-11-25 | 614.1 |
| 2021-02-01 | 853.5 | 2020-11-24 | 628.5 |
| 2021-01-29 | 847.2 | 2020-11-23 | 707.4 |
| 2021-01-28 | 849.0 | 2020-11-20 | 696.6 |
| 2021-01-27 | 824.1 | 2020-11-19 | 659.3 |
| 2021-01-26 | 866.1 | 2020-11-18 | 640.6 |
| 2021-01-25 | 880.0 | 2020-11-17 | 641.8 |
| 2021-01-22 | 890.0 | 2020-11-16 | 632.0 |
| 2021-01-21 | 904.4 | 2020-11-13 | 655.2 |
| 2021-01-20 | 907.3 | 2020-11-12 | 650.1 |
| 2021-01-19 | 885.7 | 2020-11-11 | 644.8 |
| 2021-01-15 | 881.8 | 2020-11-10 | 625.0 |
| 2021-01-14 | 941.8 | 2020-11-09 | 661.7 |
| 2021-01-13 | 931.3 | 2020-11-06 | 664.4 |
| 2021-01-12 | 925.3 | 2020-11-05 | 643.1 |
| 2021-01-11 | 895.2 | 2020-11-04 | 641.8 |
| 2021-01-08 | 896.7 | 2020-11-03 | 599.1 |
| 2021-01-07 | 861.0 | 2020-11-02 | 590.3 |
| 2021-01-06 | 829.1 | 2020-10-30 | 642.6 |
| 2021-01-05 | 855.8 | 2020-10-29 | 648.8 |
| 2021-01-04 | 849.1 | 2020-10-28 | 607.3 |
| 2020-12-31 | 910.7 | 2020-10-27 | 629.0 |
| 2020-12-30 | 916.5 | 2020-10-26 | 639.5 |
NovoCure PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Compare
NYSE:HRC
NAS:RGEN
NYSE:HAE
NAS:ICUI
NAS:XRAY
NAS:IRTC
NYSE:NVST
NYSE:VAR
NAS:MMSI
NAS:ATRC
NYSE:BDX
NAS:ISRG
XPAR:EL
NYSE:BAX
OCSE:COLO B
TSE:7741
XSWX:ALC
TSE:4543
XPAR:DIM
NYSE:RMD
Address
Grenville Street, No. 4 The Forum, Saint Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.